Therative today announced it has received clearance from the Food & Drug Administration (FDA) to begin marketing ThermaClear, its innovative hand-held consumer medical device for the treatment of acne. The company also announced it has closed an additional round of expansion financing, bringing total capital raised to over $5 million. Therative will use the funds to help launch ThermaClear into the marketplace. Leading the round were Foundation Capital, RWI Ventures and Band of Angels.

"FDA clearance and the additional funding are two important milestones in our development," said Peter Scocimara, CEO of Therative. "Acne is a pervasive condition that has been without an effective solution. The FDA has cleared the way for us to bring our device to market and we intend to change the way people treat acne with our unique approach and ground-breaking technology."

"We are very pleased with the confidence our financial partners have expressed in ThermaClear and the Therative team," added Scocimara.

TGC Ventures International to Introduce All Natural Product for ...

ATLANTA, Jan. 10, 2007 (PRIME NEWSWIRE) -- TGC Ventures International (Pink Sheets:TGVI) will begin production of an all-natural product that offers relief for sufferers of psoriasis and other skin conditions. The company intends to develop and introduce the product in Hong Kong and other Asian markets.

TGC Ventures Int., motivated by the growing acceptance of homeopathic and natural remedies world wide, will head up the marketing campaign from their new head office located in Hong Kong.

Psoriasis Complex 7003 offers proven efficacy for skin conditions such as acne, rosacea and psoriasis. In studies, Complex 7003 has proven to be up to 50% more effective in comparison to pharmaceutical and cosmetic products in reducing inflammation. In a Vivo Test carried out on 2 panels of 50 volunteers, Complex 7003 again improved the clinical signs of skin sensitivity by more than 60% over a 28 day period versus a placebo.